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In  chronic  lymphocytic  leukaemia  (CLL),  lipoprotein  lipase  (LPL)  mRNA  overexpression  is an  established
poor  prognostic  marker,  its function,  however,  is  poorly  understood.  Measuring  extracellular  LPL enzy-
matic  activity  and  protein,  we found  no difference  between  levels  in CLL  patients  and  those  of  controls,
both  before  and  after  heparin  treatment  in  vivo  and  in vitro.  Investigating  LPL  knock  down  effects,  wevailable online 7 March 2013
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unctional role
determined  ﬁve  potential  downstream  targets,  of which  one  gene,  STXBP3,  reportedly  is  involved  in  fatty
acid  metabolism.
While possibly  reﬂecting  an  epigenetic  switch  towards  an incorrect  transcriptional  program,  LPL  over-
expression  by  itself  does  not  appear  to  signiﬁcantly  inﬂuence  CLL  cell survival.
© 2013 Elsevier Ltd. Open access under CC BY-NC-ND license. 
nock  down
. Introduction
Chronic lymphocytic leukaemia (CLL) is the most frequent
eukaemia in Western countries. Median age at diagnosis is 64–70
ears, survival times differ considerably between patients and
ange from normal life expectancy (>20 years) to a few years in
igh-risk groups [1,2]. Prognostic factors include clinical staging
ystems (Rai and Binet), cytogenetics, serum markers, expression
f surface molecules, and genetic markers, particularly the muta-
ional status of immunoglobulin heavy chain variable region genes
IGHV) [1,3–6]. Several surrogate markers for IGHV mutational
tatus have been identiﬁed in recent years, ZAP-70 protein and lipo-
rotein lipase (LPL) mRNA expression being the most reliable ones
7–11]. LPL predicts overall and treatment free survival [12–18].
PL mRNA expression alone or integrated into scoring systems have
stablished its prognostic value in CLL [19–22].
∗ Corresponding author at: Medical University of Vienna, Department of Medicine
,  Division of Hematology and Hemostaseology, Waehringer Guertel 18-20 1090
ienna, Austria. Tel.: +43 1 40400 73781; fax: +43 1 40400 73595.
E-mail  address: katrina.vanura@meduniwien.ac.at (K. Vanura).
145-2126 ©  2013 Elsevier Ltd. 
ttp://dx.doi.org/10.1016/j.leukres.2013.02.008
Open access under CC BY-NC-ND license. Given the central role of LPL in lipid metabolism it is attractive
to speculate on the impact of its overexpression on the survival of
CLL cells. However, data on the functional role of LPL in CLL are
very rare and in part conﬂicting. Our previous data suggest that LPL
protein is also found on the cell surface of CLL cells but that mRNA
overexpression is mainly associated with an increase of intracellu-
lar LPL protein [23]. We therefore hypothesized that CLL cells can
synthesize LPL protein that in part is secreted and bound to the cell
membrane [12]. A correlation of LPL mRNA with protein expression
in CLL was also observed by Mansouri and colleagues, who sug-
gested that the majority of protein might be catalytically inactive
[24]. On the other hand, Wendtner and colleagues suggested that
lipid metabolism is causally related to the survival of CLL cells based
on the induction of apoptosis by tetrahydrolipostatin (Orlistat) or
erufosine, a synthetic phospholipid analogue with antineoplastic
activity, treatment ex vivo [25,26]. In vivo, decreased high density
lipoprotein cholesterol (HDL-C) levels were observed in the plasma
of CLL and ALL patients compared to healthy individuals [27]. Nev-
ertheless, so far there are no published data, which prove a distinct
and speciﬁc functional role of LPL in CLL.
LPL function is best characterized in endothelial cells [28,29].
LPL is produced in parenchymal cells and transported to
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ndothelial cells that bind LPL by heparan sulfate–proteoglycan
HSPG) on the luminal cell surface [28]. Intravenous injection of
eparin competes for these HSPG binding sites and liberates LPL
nto circulation, leading to an increase in LPL plasma protein con-
entration and enzymatic activity [28]. This so called post heparin
ipolytic activity (PHLA) is an established diagnostic test for lipid
etabolism disorders.
In  the present study we assessed LPL protein concentration and
nzyme activity in serum and plasma of CLL patients with high
r low LPL mRNA expression before and after heparin treatment.
hese in vivo experiments were complemented by in vitro treat-
ent of CLL primary cells with heparin and puriﬁed LPL protein. LPL
nockdown in CLL cells by siRNA was performed to study changes
n functional behaviour of CLL cells and gene expression.
. Patients, materials and methods
.1.  Patients
A total number of 114 fully characterized, untreated chronic lymphocytic
eukaemia  patients diagnosed at the Division of Haematology at the Medical Univer-
ity of Vienna (Austria) were retrospectively screened for LPL mRNA expression and
urvival curves were calculated. In this cohort, we conﬁrmed the prognostic power
f LPL mRNA expression regarding OS and TFS (Supplementary data and Supplemen-
ary Fig. 1). Forty-two patients, for which serum and plasma samples were available,
ere studied with respect to LPL protein levels in serum and LPL enzymatic activity
n plasma. Of these 42 patients, thirteen patients were selected to study LPL release
fter heparin injection. Seventeen of these patients were selected for LPL knock
own experiments. Selection criteria were (1) availability of material needed for
nock down and (2) high LPL mRNA expression at sample date, with the goal to max-
mize mRNA expression reduction through knock down. All patients were untreated.
asic clinical information for the study cohorts is listed in Supplementary Table 1.
hree healthy individuals (HIs) and 14 non-CLL patients (lymphoma patients in com-
lete remission) served as controls. All participants gave informed consent according
o the Declaration of Helsinki, approval of the institutional Ethics Committee was
btained for this study (Ethics Committee number: 035/2007). Serum, plasma and
eripheral blood cells were collected. Peripheral blood mononuclear cells (PBMC)
ere isolated using standardized Ficoll–Hypaque gradient centrifugation (Seromed,
erlin, Germany).
.2.  Cell culture
Primary CLL PBMC, cells of the cell lines HeLa (cervix carcinoma), Hep3B (hepa-
ocellular carcinoma), CCL228 (colon carcinoma), THP1 (monocytic leukaemia) and
PMI8226 (plasma cells of multiple myeloma) were cultured at 37 ◦C and 5% CO2
n GIBCO RPMI 1640 (Life Technologies, Carlsbad, CA, USA) containing 10% foetal
alf serum (FCS Gold), 1% penicillin/streptomycin (PS) and 1% l-glutamine (all PAA
aboratories, Linz, Austria).
.3.  Heparin provocation test in vivo
To  investigate in vivo mobilization of LPL in CLL patients (PHLA), a heparin release
tudy on a cohort of 13 fully characterized CLL patients, was performed. This cohort
epresents consecutive CLL patients, which consented in writing to participate in
his part of the study. Patients received 50 U/kg body weight of standard heparin
ntravenously  (Heparin Immuno, Baxter BioScience, Vienna, Austria). Serum and
lood samples were collected before, 10 and 20 min  after heparin injection. LPL
rotein levels in serum, LPL enzymatic activity in plasma, LPL mRNA expression
n  PBMC and viability of CD3, CD14 and CD19 positive cells were investigated in
ll samples. For ethical reasons, published values of healthy individuals before and
fter heparin administration were used as reference.
.4. Heparin provocation test and LPL treatment in vitro
LPL mobilization in vitro was assessed in three (one mutated and two  unmu-
ated)  CLL samples. Immediately after Ficoll isolation, PBMC were washed twice
ith phosphate-buffered saline (PBS), counted and 5 × 106 cells were cultured in
 ml serum-free GIBCO RPMI 1640 containing 1% PS for 2 h at 37 ◦C and 5% CO2. Then
ells were treated with 20 U standard heparin. After 20 min  of incubation, super-
◦atant  was harvested and stored at −20 C for LPL protein and enzymatic activity
easurements.  Cells were instantly stained and apoptosis was  analyzed by ﬂow
ytometry. THP1 cells cultured and treated under the same conditions were used
s positive control. To evaluate the effect of external LPL on cell viability, cells of
he 3 CLL patients were cultured and treated for 24, 48 and 72 h with 10, 100, 1000,
nd 10,000 ng/ml of puriﬁed LPL protein (Sigma, St. Louis, MO,  USA). Apoptosis was
nvestigated by ﬂow cytometry.earch 37 (2013) 631– 636
2.5.  LPL protein levels and enzymatic activity
Pre-heparin serum and plasma of 42 CLL, 14 non-CLL patients (lymphoma
patients  in complete remission) and 3 HIs, as well as pre- and postheparin serum
and  plasma from 13 CLL patients selected for heparin provocation tests were col-
lected and stored at −20 ◦C until further analysis. Enzyme-linked immunosorbent
assay  (ELISA) was performed using the LPL EIA kit (ALPCO diagnosticsTM, Salem, NH,
USA) according to the manufacturer’s instructions. Before use, serum was diluted
1:30. Linearity of the assay system was observed from 9 to 500 ng/ml, the coefﬁ-
cient  of variation (Cv) was less than 10% (within-run). LPL enzymatic activity assays
were carried out at the Department of Molecular Biology and Biochemistry at the
University of Graz as described elsewhere [30].
2.6.  LPL mRNA expression
RNA and cDNA preparation and real-time PCR were carried out as described
previously  (LPL TaqMan assay-on-demand: Cat. No. Hs00173425 m12, Life Tech-
nologies, Carlsbad, CA, USA) [12].
2.7. Apoptosis and viability
To  determine cell phenotype, PBMCs were washed with PBS and re-suspended
in  0.3% BSA (bovine serum albumin) and 0.1% Na-azide (both Sigma, St. Louis, MO,
USA). Nonspeciﬁc binding was  blocked by 20% human AB serum (Cat. No. C11-
021,  PAA Laboratories, Linz, Austria) in PBS/BSA. Cells were stained with mouse
anti-human  CD3, CD19, CD14 – PE (BD Biosciences, San Diego, CA, USA) using the rec-
ommendations of the manufacturer. Cells were incubated for 30 min on ice, washed,
re-suspended in 0.2 ml  PBS/BSA and analyzed on a Becton Dickinson FACScan. For
each analysis 10,000 events were acquired and analyzed using the CellQuestPro
software.
For  apoptosis detection, the Annexin-V detection kit (Bender MedSystems,
Vienna,  Austria) was  used according to the manual and analyzed on the BD FAC-
Scan. The rate of cellular apoptosis was calculated as the percentage of Annexin
positive  cells.
Viability was detected using the Cell-Titre Blue Assay according to the instruc-
tions  of the manufacturer (Promega, Madison, WI,  USA).
2.8.  Transfection of primary CLL cells
Stealth Select 3 RNAiTM set designed to silence human LPL, Stealth RNAiTM
scrambled siRNA negative controls for high and low GC-content, and Block-iTTM
positive control Fluorescent Oligo for lipid transfection were acquired from Life
Technologies (Carlsbad, CA, USA). All three siRNAs targeting LPL were tested and
the most effective was  used for subsequent experiments. PBMC of 10 CLL patients
with  high LPL mRNA expression were selected for knock down experiments. Cells
were thawed, counted and 10 × 106 cells per well were plated in 6-well cell culture
plates  using 2 ml  phenol red free GIBCO RPMI 1640 (Life Technologies, Carlsbad, CA,
USA) containing 10% FBS, 1% l-glutamine, and 1 ng/ml TPA (phorbol-12-myristate-
13-acetate, Sigma Aldrich, St. Louis, MO,  USA). Cells were then incubated for 1 h at
37 ◦C. RNAi duplexes and 15 l LipofectamineTM 2000 Reagent (Life Technologies,
Carlsbad,  CA, USA) were diluted in 500 l Opti-MEM (Life Technologies, Carlsbad, CA,
USA) and incubated for 20 min  at room temperature according to the manufacturer’s
instructions.  Five hundred microlitres of StealthTM RNAi-Lipofectamin complexes
were  added to each well, ﬁnal siRNA concentration was 60 pmol/ml. Each trans-
fection  was  performed in duplicate. After 24 h, 1 ml of fresh medium was added
to  each well. After 48 h, cells were harvested, washed with ice-cold PBS and RNA
was prepared using TRIzol. Transfection efﬁciency and effect on cell viability were
monitored by ﬂow cytometry. LPL mRNA expression was measured in all samples
(negative  control, mock transfection, transfection with scrambled siRNA and trans-
fection with siRNA speciﬁc against LPL). The ratio in percent of LPL mRNA expression
after  transfection with scrambled and LPL speciﬁc siRNA, respectively, represents
knock  down efﬁciency. In addition, analyses of co-regulated genes were carried out
by gene-expression proﬁling as described below.
2.9.  Transfection of cell lines
One  day before transfection, cells were seeded in 2 ml culture medium without
antibiotics.  At 70–80% conﬂuence, cells were transfected. HeLa, Hep3B and CCL228
cells  were transfected using LipofectamineTM 2000 following the cell speciﬁc trans-
fection protocols of the manufacturer. RPMI8226 and THP1 cells were transfected
using  LipofectamineTM RNAiMAX according to the manufacturer’s instructions for
THP1 cells. This protocol was  modiﬁed in one particular aspect: similar to CLL cells,
THP1 cells were treated with 1 ng/ml TPA 1 h prior to transfection.
2.10. Microarray analysisTo  determine genes up or down regulated after LPL knock down, RNA from
paired  samples (transfected with scrambled siRNA vs. LPL speciﬁc siRNA from the
same time point) was extracted as described above, puriﬁed using the RNeasy Mine-
lute kit (QIAGEN Inc., Valencia, CA, USA). Total RNA (200 ng) was then used for
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eneChip analysis. Preparation of terminal-labelled cDNA, hybridization to genome-
ide human Gene Level 1.0 ST GeneChips (Affymetrix, Santa Clara, CA, USA) and
canning of the arrays were carried out according to manufacturer’s protocols
https://www.affymetrix.com).
.11.  Bioinformatic analysis
The  R Bioconductor Suite (http://www.R-project.org/Bioconductor) has been
sed for the analysis of the microarray data. RMA  was  used for normalization [31].
ierarchical clustering was  performed using Pearson‘s correlation coefﬁcient as
istance measure and ward‘s optimization criteria to cluster genes and samples,
espectively.  Gene expression data are available at the GEO database under the
ccession number GSE44247.
. Results
.1. LPL protein levels and activity in the serum or plasma of CLL
atients
LPL  concentrations were measured in the serum of CLL patients
ith various LPL mRNA levels at baseline and after administration
f intravenous heparin using standard methods. No differences in
re-heparin LPL serum protein levels or enzymatic activity were
bserved when comparing 42 CLL vs. 14 non-CLL patients vs. 3
ealthy individuals (Fig. 1A). Prognostic subgroups within CLL
atients (M vs. UM, high LPL mRNA vs. low LPL mRNA) showed no
igniﬁcant differences (Fig. 1B). LPL serum protein concentration
nd plasma activity of CLL patients increased after heparin injection
n vivo (N = 13; patient characteristics listed in Supplementary Table
). Measured levels were in the range of those expected in healthy
ubjects reported in the literature (Table 1) [30,32–34]. Impor-
antly, no signiﬁcant difference was observed between patients
ith high or low LPL mRNA expression in their CLL cells collected
t the same time (Table 1).
In line with this observation, no LPL mobilization from CLL
ells could be observed after heparin treatment in vitro. Cell via-
ility remained unaffected both in vivo and in vitro after heparin
reatment and in vitro after incubation with LPL protein (data not
hown).
.2. LPL knock down experiments
In  order to determine the functional impact of LPL expression
e performed siRNA knock down in primary CLL PBMC and control
ell lines, all expressing high LPL mRNA levels (HeLa (expression
evel 241.77), Hep3B (548.74), CCL228 (74.87), THP1 (51.67 before
nd 157.31 after stimulation with TPA), and in RPMI8226 cells
121.30). Tumour load and knock down efﬁciencies are summa-
ized in Supplementary Table 3. Highest knock down (up to 90%)
ould be reached in adherent cell lines followed by suspension cell
ines and CLL primary cells. The rate of apoptosis in all cell lines
even in those with the highest knock down efﬁciency) and CLL
amples was not different in samples transfected with LPL target-
ng or scrambled siRNA (Supplementary Fig. 2). Comparing a time
eries up to 72 h, we observed an optimal knock down to apoptosis
atio at 48 h (data not shown).
Due to knock down heterogeneity among CLL samples, only
xperiments showing an LPL knock down of at least 25% after 48 h
10 of 17) were selected for microarray analysis (median knock
own efﬁciency: 33%; range: 25–54%; Supplementary Table 3).
icroarray analysis was  also performed in the ﬁve cell lines listed
bove. In unsupervised clustering gene expression proﬁles after
nock down in THP1 cells were most similar to CLL. Among CLL
amples, two main clusters (three vs. seven samples) with similar
ene expression proﬁle after knock down were identiﬁed. No clin-
cal differences were found between patients belonging to either
luster (data not shown).earch 37 (2013) 631– 636 633
Correlating gene signal intensity and knock down strength, fold
changes were calculated for the entire study cohort. Considering a
maximum LPL knock down efﬁciency of 54% in primary CLL cells, we
selected the following criteria to achieve the most reliable output
regarding speciﬁc knock down related changes in gene expression:
a cut-off of at least 20% deregulated expression in at least 7 of the 10
primary samples. The resulting genes were then ranked according
to the number of CLL samples with similar de-regulation. In total, 33
genes were down-, and 3 genes were up regulated in at least 7 of 10
samples after LPL knock down (Supplementary Fig. 3). Applying a
similar restriction to the cell lines, 20% deregulation in at least three
of the ﬁve cell lines, no overlap in deregulated genes were found
between cell lines and CLL samples. Even comparing single cell lines
with the CLL cohort, no overlapping genes (at 20% deregulated)
could be observed.
Six  genes downregulated in 8 of 10 CLL samples were selected
for validation with additional samples. Again, 25% LPL knock down
efﬁciency was  set as cut off. After this second round of transfections
(N = 7) and measuring gene expression of the selected genes by real
time PCR, the following 5 genes showed signiﬁcant downregulation
together with LPL: LMAN1 (lectin, mannose-binding 1), STXBP3
(syntaxin-binding protein 3), LARP7 (La ribonucleoprotein domain
family, member 7), RANBP2 (RAN-binding protein 2), SSB (Sjogren
syndrome antigen B) (Table 2). Of these, STXBP3 might be a down-
stream target of LPL since parallel regulation has been described in
conjunction with fatty acid induced insulin resistance of skeletal
muscle [35]. Our data show that LPL knock down is associated with
speciﬁc expressional changes in CLL cells but not necessarily with
changes in cell survival at least in short term experiments.
4. Discussion
Reports are accumulating, that fatty acid metabolism is altered
in human malignancies [36–38]. LPL, a key enzyme in lipid
metabolism, is known to hydrolyze circulating triglyceride-rich
lipoproteins. Absence or decreased LPL activity causes an increase
of plasma triglycerides (TG) coinciding with reduced HDL-C lev-
els [28,39]. Accordingly, decreased HDL-C plasma levels were
reported in patients suffering from lymphoid leukaemia [27]. Hep-
arin injection inﬂuences LPL activity, by binding and displacing LPL
from HSPG binding sites. Only active as non-covalent homodimer,
dimeric LPL appears to have much higher afﬁnity for heparin and
HSPG compared to its monomeric form [28].
Here we  provide novel in vivo data on the behaviour of LPL pro-
tein concentration and activity under basal conditions and after
i.v. heparin injection. Serum LPL protein concentrations were sim-
ilar in 42 CLL patients compared to 14 non-CLL controls and 3 HI.
This was also true for high and low LPL mRNA expressing patients.
The functional post-heparin test leads to an increase of LPL protein
concentration in serum and activity in plasma in normal subjects.
Surprisingly, both LPL serum levels and enzymatic activities in CLL
patients were comparable to those found in healthy individuals
according to data reported in the literature [32,33]. Considering
the higher lymphocyte counts in CLL patients compared to healthy
individuals, and the fact that LPL protein has been demonstrated
in CLL cells [12], one would have expected a much higher increase
in LPL protein concentration, in high LPL expressing cases. Thus,
our ﬁndings could indicate that (i) part of the LPL is retained by an
alternative mechanism on the surface of CLL cells leaving it non-
responsive to heparin treatment, (ii) that the amount of surface
LPL on CLL cells is much less than previously thought, and/or (iii)
LPL in CLL exists mostly as non-active monomer. Alternatively LPL
might be bound by lymphocytes similarly as described for endothe-
lial cells [28] yet their release might be blocked. Our in vitro data
support this hypothesis since (i) post-heparin LPL levels resembled
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Fig. 1. (A) Box plot showing LPL protein concentrations in the sera of CLL patients (N = 42) vs. non-CLL patients (lymphoma patients in complete remission; N = 14) vs. healthy
donors (N = 3). (B) Box plot showing LPL protein concentrations in the sera of CLL patients (N = 42) according to high and low mRNA expression (N = 16 in high expressing,
N = 26 in low expressing group).
Table  1
Median LPL protein serum concentration (ng/ml) and plasma activity (M/ml/h) upon heparin treatment in vivo. Data listed correspond to before (0), 10 and 20 min
after heparin injection. Normal range according to literature: LPL protein mass 40.3 ± 14.42 ng/ml [34] and 58.3 ± 43.5 ng/ml [33] pre-heparin; 334.1 ± 71.5 ng/ml [34] and
323  ± 40.6 ng/ml [33] post-heparin. Post-heparin LPL activity range of 3.33–24.41 M/ml/h in normal subjects. [30].
LPL protein 0 (ng/ml) LPL protein 10 (ng/ml) LPL protein 20 (ng/ml)
CLL patients with high LPL mRNA expression (N = 5) 16.11 214.33 332.78
CLL  patients with low LPL mRNA expression (N = 8) 13.08 219.68 386.65
LPL activity 0 (M/ml/h) LPL activity 10 (M/ml/h) LPL activity 20 (M/ml/h)
t
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eCLL patients with high LPL mRNA expression (N = 5) 7.25
CLL patients with low LPL mRNA expression (N = 8) 7.45 
hose of normal individuals and (ii) heparin incubation of CLL cells
x vivo did not result in elevated LPL levels in the supernatant under
erum-free conditions.
Our  observations complement data published by Mansouri et al.
24] who showed that LPL protein expression follow LPL mRNA
xpression in CLL subgroups deﬁned by IGHV mutational status.
sing cell lysates, these authors found extremely low levels of
PL activity. To determine speciﬁc LPL activity in mutated and
nmutated cases, they used the ratio of LPL activity per amount
f LPL protein expressed. LPL in mutated cases showed statistically
igniﬁcant higher speciﬁc activity compared to unmutated cases.
his would indicate that, while having lower mRNA and protein
xpression, LPL in mutated CLL cases is more active compared to
nmutated cases. Based on the low levels of LPL activity in total,
owever, the authors concluded that a function of catalytically
ctive LPL in CLL might be questionable. Such a low enzyme activity
ould ﬁt well with the reported reduced HDL-C levels in leukaemia
atients [27].
able 2
ist  of genes which were co-regulated with LPL knock down in microarray analysis (N = 10
fﬁciencies in validation experiments in an additional set of 7 samples detected by real ti
Gene symbol Knock down-microarray analysis (N = 10) 
Downregulation in N samples Median relative downregulation
LMAN1a 8 −34 
RANBP2b 8 −53 
SSBc 8 −41 
STXBP3d 8 −28 
LARP7e 8 −26 
a LMAN1 (lectin, mannose-binding 1): type 1 integral membrane protein, mannose-spe
b RANBP2 (RAN-binding protein 2): GTP-binding protein of the RAS superfamily, localiz
c SSB (Sjogren syndrome antigen B): RNA-binding protein, involved in various aspects 
d STXBP3 (syntaxin-binding protein 3): involved in fatty acid induced insulin resistanc
e LARP7 (La ribonucleoprotein domain family, member 7): RNA-binding protein and tr15.52 19.13
20.01 20.57
Taken together, these data suggest that the general impact
of high LPL expression in high-risk CLL cells on lipoprotein
metabolism might be low due to the lack of active secretion of LPL.
Noteworthy in this respect is the absence of noticeable effects in
lipid metabolism in high-risk CLL patients. This could point to a
possible function as a surface receptor or bound bridging molecule
[28,39]. In addition, an intracellular function may be operative as
high LPL mRNA expression is associated with a high cytoplasmic
protein expression [12].
If  LPL plays a role in energy supply for CLL cells one could expect
better survival of tumour cells when supplied with LPL under cell
culture conditions. However, when incubating primary CLL cells
with puriﬁed LPL protein in vitro with and without FCS, we  could
not observe any changes in cell viability and LPL mRNA expression
in high and low expressing CLL cases vs. negative controls. Since CLL
cells are known to enter apoptosis relatively soon when cultured
without feeder cells, one would have expected a survival advantage
when supplemented with LPL. Our results might indicate that LPL
) and subsequently selected for validation. The last two columns show knock down
me PCR. Negative values represent downregulation after LPL knock down.
Knock down-validation and real time PCR (N = 7)
 (%) Downregulation in N samples Median relative downregulation (%)
6 −29
4 −39
4 −23
6 −18
5 −17
ciﬁc lectin.
ed in the nuclear membrane, involved in nuclear-cytoplasmic transport of proteins.
of RNA metabolism.
e in skeletal muscle cells.
anscription factor.
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predictors in CLL patients in remission following treatment with oral ﬂudara-
bine plus cyclophosphamide. Ann Hematol 2009;88(12):1215–21.E. Porpaczy et al. / Leukem
rotein supplemented in the culture medium is not taken up by the
ells or, if so, does not inﬂuence cell survival. Likewise, cell survival,
oth in vivo and in vitro, and LPL mRNA expression were unaffected
y heparin treatment.
In  this context it is noteworthy that Pallasch et al. compared
PL activity between CLL cells and B-cells of healthy individuals
nd found 4.5-fold higher activity in CLL in cell lysates, which
nclude, in contrast to our study, both cell surface and intracellu-
ar LPL [25]. They did not compare LPL activity between high and
ow LPL expressing CLL patients. Treating cells with Orlistat, they
bserved a decrease of LPL activity in CLL lysates and an increase
n apoptosis compared to healthy B-cells and PBMC. However, the
uthors did not ﬁnd LPL speciﬁc susceptibility to Orlistat in CLL
ince the effect of this lipase inhibitor was similar in LPL negative
nd LPL positive sample groups. In addition, this work group evalu-
ted the inﬂuence of erufosine, which also targets lipid metabolism,
nd found higher induction of apoptosis in CLL cells compared to
ealthy PBMC [26].
In  order to further address a possible functional role of LPL for
ymphocyte survival in CLL, we have performed a speciﬁc knock
own of LPL by siRNA. With all limitations of this technique in
LL cells, which are difﬁcult to transfect, we could not observe
n increased cell death within 48 h. Nevertheless, a small num-
er of genes appeared to be coregulated with LPL, in particular
TXBP3. Interestingly, STXBP3 has been shown to be involved
n fatty acid induced insulin resistance in skeletal muscle cells.
lso, with human LPL stably transfected C2C12 myoblast cells
ad increased levels of STXBP3 mRNA and protein [35]. These
ata, together with our results, indicate that this gene behaves
s a downstream target of LPL. LMAN1, a type 1 integral mem-
rane protein, is a mannose-speciﬁc lectin. It stimulates IgM
olymerization and mutations in the gene are associated with
oagulation defects [40]. LARP7 is a RNA-binding protein and
ranscription factor. In gastric cancer, LARP7 was  found to func-
ion as tumour suppressor gene [41]. SSB (LARP3), like LARP7 a
NA-binding protein, also is involved in various aspects of RNA
etabolism. RANBP2, a GTP-binding protein of the RAS superfam-
ly, is localized in the nuclear membrane being involved particularly
n nuclear-cytoplasmic transport of proteins. In addition, it has
een reported to be fused to ALK in atypical myeloproliferative
eukaemia in children resulting in a RANBP2-ALK fusion transcript
42]. This low number of LPL co-regulated genes is due to the
iological heterogeneity among CLL samples, the known difﬁcul-
ies, when applying knock down techniques to primary CLL cells,
nd to the hence necessarily very restrictive bioinformatic analy-
is.
Lipoprotein lipase mRNA expression is an excellent prognostic
arker in CLL. What causes LPL overexpression, however, is not
lear and studies are complicated by the fact that the regulation
f this gene is tissue speciﬁc at transcriptional, posttranscriptional
nd posttranslational levels [43]. In this respect, a study reported
nly recently that external stimuli induced demethylation of the
1 region of LPL leading subsequently to an upregulation of LPL
xpression both on mRNA and protein level [44]. The functional
onsequences of LPL mRNA overexpression, however, are unclear.
lterations in lipid metabolism as reported for a number of malig-
ancies [36–38] might suggest an involvement in tumour energy
upply and, potentially, survival advantage. All our experiments,
n contrast, fail to show such a role for LPL at least in short-term
xperiments.
Further studies will be necessary to uncover a role of LPL in CLL,
n particular, long term co-culture observations of CLL cells with
table LPL knock down are warranted. Furthermore, it may not be
uled out that LPL overexpression is the consequence of general
ellular stress in the tumour cells and therefore a lack of functional
igniﬁcance in CLL may  not be excluded.
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